Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity by Smith, Steve R. et al.
Sustained Weight Loss Following
12-Month Pramlintide Treatment as an
Adjunct to Lifestyle Intervention in Obesity
STEVE R. SMITH, MD
1
LOUIS J. ARONNE, MD
2
COLLEEN M. BURNS, PHD
3
NICOLE C. KESTY, PHD
3
AMY E. HALSETH, PHD
3
CHRISTIAN WEYER, MD
3
OBJECTIVE — To assess long-term weight loss efﬁcacy and safety of pramlintide used at
different dosing regimens and in conjunction with lifestyle intervention (LSI).
RESEARCH DESIGN AND METHODS — In a 4-month, double-blind, placebo-
controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six
arms: 120, 240, and 360 g b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI
program geared toward weight loss. Of the 4-month evaluable subjects (n  270), 77% opted to
continue preexisting treatment during an 8-month single-blind extension (LSI geared toward
weight maintenance).
RESULTS — Atmonth4,meanweightlossfrombaselineinthepramlintidearmsrangedfrom
3.80.7to6.10.8kg(2.80.8kgwithplacebo).Bymonth12,initial4-monthweightloss
was regained in the placebo group but was maintained in all but the 120-g b.i.d. group.
Placebo-corrected weight loss with 120 g t.i.d. and 360 g b.i.d. averaged 3.2  1.2 kg (3.1 
1.1%bodywt)and3.31.1kg(3.11.0%bodywt),respectively,atmonth4(bothP0.01;
4-month evaluable n  270) and 6.1  2.1 kg (5.6  2.1% body wt) and 7.2  2.3 kg (6.8 
2.3% body wt), respectively, at month 12 (both P  0.01; 12-month evaluable n  146). At
month 12, 40 and 43% of subjects treated with 120 g t.i.d. and 360 g b.i.d., respectively,
achieved10%weightloss(vs.12%forplacebo).Nausea,themostcommonadverseeventwith
pramlintide in the 4-month study (9–29% pramlintide vs. 2% placebo), was generally mild to
moderate and occurred in 10% of subjects during the extension.
CONCLUSIONS — Whenusedover12monthsasanadjuncttoLSI,pramlintidetreatment,
withlow-dosethree-times-dailyorhigher-dosetwo-times-dailyregimens,helpedobesesubjects
achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
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T
o date, efforts to develop obesity
pharmacotherapies aimed at re-
ducing food intake and body
weight have largely focused on small-
molecule anorectics, an approach that
has repeatedly been hampered by safety
concerns (1). Peptide hormones origi-
nating from pancreas and gut regulate
meal size and body weight by acting as
short-term (episodic) signals (2). In
contrast to small molecules, peptide
hormones do not readily diffuse the
blood-brain barrier to penetrate the en-
tire central nervous system. Moreover,
theyactbyenhancingsignalingthrough
speciﬁc, naturally occurring pathways
that regulate food intake as opposed to
acting more generally on multiple neu-
ronal processes, for example, by altering
synaptic concentrations of neurotrans-
mitters. Based on these characteristics,
peptide hormone therapeutics are poten-
tial alternatives to centrally-acting small-
molecule anorectics.
Amylin, a 37–amino acid -cell
hormone cosecreted with insulin in re-
sponse to meals, reduces food intake
and body weight in rodents and may
fulﬁll the criteria for a peripheral satia-
tion hormone (3–6). Pramlintide, a
synthetic analog of human amylin, has
been extensively studied as an antihy-
perglycemic treatment and is currently
under investigation as a potential treat-
ment for obesity.
In two studies in obese subjects,
pramlintide (120 g single doses or 180
g t.i.d. before meals for 6-weeks) re-
duced ad libitum food intake (7,8). Com-
pared with placebo, pramlintide
signiﬁcantly reduced 24-h caloric intake
(by 500–750 kcal) and caloric intake at
a highly palatable fast-food challenge (by
20%) and improved control of eating,
evidenced by a 45% reduction in binge-
eating score (8).
Pramlintide’sweighteffectsinobese
subjects were initially assessed in a 16-
week, randomized, double-blind, pla-
cebo-controlled, nonforced dose-
escalation study. In this study, in which
88% of subjects escalated to the maxi-
mum dose (240 g t.i.d.), pramlintide
induced a placebo-corrected reduction
in weight of 3.7% (P  0.001), with
31% of pramlintide-treated subjects
achieving 5% weight loss (versus 2%
for placebo; P  0.001) (9). Although
these ﬁndings established a solid proof
of concept for the antiobesity potential
of pramlintide, the study was limited to
4 months and did not employ lifestyle
intervention (LSI), and subjects were
not randomly assigned to different
pramlintide doses or dose frequencies.
To evaluate the weight loss efﬁcacy
andsafetyofpramlintideacrossarangeof
doses, across different dose frequencies,
in conjunction with LSI, and over 1 year,
we conducted a 4-month dose-ranging
study (main study) evaluating six pram-
lintide arms (120, 240, and 360 g b.i.d.
andt.i.d.)inconjunctionwithlifestylein-
tervention (LSI) and then implemented
an 8-month single-blind extension proto-
colinwhichsubjectscontinuedtheirpre-
assigned treatment.
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METHODS
Main double-blind study
This was a 4-month, multicenter (24 cen-
ters in the U.S.), randomized, double-
blind, placebo-controlled, dose-ranging
study. Following a 1-week placebo lead-
in, 411 obese subjects were randomized
(1:6) to receive placebo three times daily
or pramlintide (120, 240, and 360 g
b.i.d. and t.i.d.) via subcutaneous injec-
tion 15 min before morning, midday, and
evening meals in conjunction with LSI.
To maintain dose-frequency blinding,
subjects receiving pramlintide twice daily
also received placebo before midday
meals.Pramlintidewasinitiatedat120g
andincreasedin120gincrementsevery
2 weeks until the assigned maintenance
dosewasreached(onlineappendixFig.1,
available at http://dx.doi.org/10.2337/
dc08-0029).
Single-blind extension study
Subjects who completed the 4 months
without major protocol deviations (4-
month evaluable) were eligible to con-
tinue their preassigned treatment for 8
months during the single-blind exten-
sion. Following the placebo-controlled
8-month extension, pramlintide treat-
ment was continued in some subjects for
non–placebo-controlled safety assess-
ments (data not shown).
LSI program
All subjects participated in an individual-
ized LSI program (based on LEARN [10])
administered by trained study site per-
sonnel. LEARN is a commercially avail-
ableprogramforweightmanagementthat
encompasses diet, physical activity, and
behavioral modiﬁcations and has been
extensively used in pharmacological and
nonpharmacological weight loss inter-
vention studies (14). At the start of the
double-blind study, subjects were pro-
vided with a lifestyle intervention pro-
gram manual and a digital pedometer.
While LEARN provided a ﬂexible ap-
proach to LSI, subjects were generally en-
couraged to reduce their caloric intake by
500 kcal/day and increase their steps up
to 10,000 per day. At the start of the
extension (month 4), subjects received
another program manual containing ad-
ditional lessons focused on maintaining
the behavioral changes taught during the
double-blind study. Individual lifestyle
counseling sessions were conducted by
study personnel trained in the use of the
LEARN program and occurred at all
scheduled study site visits (day 1 and
weeks 2, 4, 8, and 12 of the double-blind
extension and each month during the ex-
tension). Subjects were provided with
self-monitoring forms and encouraged to
keep diet and exercise records (records
not collected as study data). At each visit,
records were reviewed and subjects were
encouraged to continue with the pro-
gram. Counseling was standardized
across study sites. LSI was geared toward
weight loss during the main study and
toward weight maintenance during the
extension.
Study participants
Subjects were obese (BMI 30 and 50
kg/m
2foratleast1year)nondiabeticmen
and women aged 18–70 years with ab-
dominal obesity (waist circumference
102 cm for men and 88 cm for
women) (11). Women were surgically
sterile, postmenopausal, or practicing ap-
propriate contraception. Other entry cri-
teria included medically nonsigniﬁcant
baseline clinical laboratory tests.
Exclusion criteria included clinically
active cardiac disease, diabetes, poorly
controlled hypertension (sitting blood
pressure 160/95 mmHg), hepatic dis-
ease, malignant disease within 5 years of
screening, major depressive or psychotic
disorders, eating disorders, gastrointesti-
nal disorders, current enrollment in a
weight loss program, and use of excluded
concomitant medications including ste-
roids and antiobesity, antipsychotic, anti-
epileptic, and certain antidepressant
agents (including monoamine oxidase in-
hibitors, bupropion, tricyclic antidepres-
sants, and tetracyclic antidepressants).
Subjects on stable doses of selective sero-
tonin reuptake inhibitors and serotonin-
norepinephrine reuptake inhibitors,
except for sibutramine, were permitted to
enroll.
The study protocol was approved by
the institutional review board of each study
site or by a centralized institutional review
board. All patients provided written in-
formed consent before the main study and
extension. This study was conducted in ac-
cordance with the principles described in
the Declaration of Helsinki (1964), includ-
ingallamendmentsuptoandincludingthe
1996 South African revision.
Study end points
The primary end points of both the main
double-blind study and the single-blind
extension were changes in body weight,
safety,andtolerability.Safetyassessments
included incidence and severity of treat-
ment-emergent adverse events. Other
safety parameters included evaluation of
concomitantmedications,physicalexam-
ination ﬁndings, vital signs, electrocar-
diograms, and clinical laboratory
measures.
Statistical analysis
For the main study, 280 subjects com-
pleting the study (57 subjects random-
ized to each treatment group) were
considered sufﬁcient to detect a signiﬁ-
cant difference of 2.2  3.4 kg in mean
 SD body weight change from baseline
to month 4 between the placebo and any
pramlintide group with 80% power at
the 0.05 signiﬁcance level. The intent-to-
treat (ITT) populations for both the main
double-blind study and the single-blind
extension included all randomized sub-
jectswhoreceivedatleastoneinjectionof
study medication within the respective
protocols. The 4- and 12-month evalu-
ablepopulationsincludedallITTsubjects
who remained in the study through
month4andmonth12(orreceivedstudy
medication for 330 days), respectively,
who did not begin treatment with any re-
strictedconcomitantmedicationandwho
had acceptable with study medication
compliance.
Summaries of safety and tolerability
were conducted separately for each study
using the corresponding ITT population.
Changes in body weight and waist cir-
cumference were analyzed separately for
each study using the corresponding ITT
and evaluable populations. Missing data
for the ITT populations were imputed us-
ing the last observation carried forward
(LOCF)method.LOCFwasimplemented
separately for each study using the corre-
sponding ITT population. Subgroup
analyses were conducted by the occur-
rence of treatment-emergent nausea in
the ITT population.
Changes in body weight from base-
line were analyzed using a general linear
model including factors for treatment
group, study site, sex, baseline BMI stra-
tum (35, 35 to 40, and 40 kg/
m
2), and baseline body weight as
covariates. P values were based on the
least squares mean differences in the
change from baseline to each visit be-
tween each active treatment group and
the pooled placebo group. The percent-
age of evaluable subjects achieving 5%
weight loss from baseline to month 4 and
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linetomonth12wasanalyzedusingFish-
er’s exact test. For all analyses, a P value
0.05 was considered statistically signif-
icant. Demographic data are presented as
means  SD. All other parameters are
presented as mean  SE.
RESULTS
Baseline characteristics and subject
disposition
Double-blind study. In the main dou-
ble-blindstudy,408(theITTpopulation)
of the 411 subjects randomized to pla-
cebo or one of six pramlintide arms
startedthestudymedication.Withdrawal
rates were slightly lower for the pooled
pramlintide group (31%) than for pla-
cebo(37%)(Table1).Overallwithdrawal
rates and reasons for withdrawal were
generally similar between all pramlintide
treatment arms.
Single-blind extension. Of the eligi-
ble subjects (4-month evaluable n 
270), 77% opted to participate in the
single-blind extension. By month 12,
withdrawal rates were 26% for pram-
lintide-treated versus 37% for placebo-
administered subjects (Table 1).
Baseline characteristics of subjects par-
ticipating in the single-blind extension
were well balanced across arms in each
study (Table 1).
Body weight and waist
circumference
Double-blind study. In the placebo
group, weight loss at 4 months averaged
2.8  0.8 kg (evaluable 2.6  0.7%; ITT-
LOCF 1.8  0.5 kg [1.6  0.5%]) (Fig.
1A and B). By comparison, weight loss
from baseline to month 4 in the pramlint-
idetreatmentarmsrangedfrom3.80.7
to 6.1  0.8 kg (evaluable 3.9  0.7 to
5.7  0.9%; ITT-LOCF 2.8  0.5 to
4.7  0.7 kg [2.9  0.5 to 4.3  0.6%]).
Pramlintide at 120 g t.i.d. and 360 g
b.i.d. and t.i.d. achieved statistically
signiﬁcant reductions in absolute body
weight versus placebo at month 4
(evaluable and ITT-LOCF P  0.05).
Table 1—Baseline demographics for the ITT population and subject disposition, N  349
Placebo
Pramlintide
120 g b.i.d. 120 g t.i.d. 240 g b.i.d. 240 g t.i.d. 360 g b.i.d. 360 g t.i.d.
Double-blind study
Sex (% female) 73 73 71 72 75 71 73
Age (years) 47  12 43  11 46  12 45  14 44  14 44  12 46  13
Race, W/B/H/O 71/17/12/0 61/24/15/0 66/17/15/2 70/15/11/4 70/16/13/2 75/9/14/3 76/13/10/2
Body weight (kg) 104.0  17.8 105.1  19.9 105.6  18.0 107.7  19.5 104.7  19.2 106.9  22.1 108.1  17.2
BMI (kg/m
2) 37.2  4.4 37.5  5.0 37.7  5.1 38.1  5.4 37.2  4.9 37.8  5.5 37.7  4.6
Waist circumference
(cm)
112.9  12.6 112.4  15.0 114.2  12.3 116.2  15.2 114.7  13.7 114.6  14.3 114.6  11.7
4-month ITT (n) 5 95 95 95 45 65 96 2
Withdrew (%) 37 32 36 37 20 32 27
Withdrawal of
consent (%)
19 10 12 7 4 10 2
Adverse event (%) 037759 1 6
Other (%) 19 19 17 22 11 14 10
Completed 4 months
(n)
37 40 38 34 45 40 45
4-month evaluable (n) 3 63 83 83 24 53 94 2
Single-blind extension*
Sex (% female) 78 75 72 80 80 66 79
Age (years) 49  11 45  11 48  10 44  14 46  13 44  13 47  12
Race, W/B/H/O 82/11/7/0 64/25/11/0 76/14/10/0 72/16/8/4 77/7/17/0 88/3/6/3 84/8/8/0
Body weight (kg) 105.8  17.9 102.6  16.3 106.4  18.0 107.0  21.1 104.0  21.0 108.8  20.4 106.9  15.6
BMI (kg/m
2) 37.7  4.8 37.1  4.3 37.6  4.8 38.1  5.7 37.1  4.8 37.8  5.9 38.0  4.5
Waist circumference
(cm)
113.1  14.3 110.3  13.3 115.2  12.2 116.2  16.0 114.8  14.9 115.3  13.7 114.5  10.7
12-month ITT (n) 2 72 82 92 53 03 23 8
Withdrew (%) 37 14 14 28 17 31 47
Withdrawal of
consent (%)
2 6 71 01 21 02 23 4
Adverse event (%) 0000033
Other (%) 11 7 3 16 7 6 11
Completed 12 months
(n)
17 24 25 18 25 22 20
12-month evaluable
(n)
17 25 25 17 23 21 18
Data are means  SD unless otherwise indicated. Numbers may not add up to 100% due to rounding. C/B/H/O  White/Black/Hispanic/other. *Demographics for
participants of single-blind extension at baseline and prior to starting the double-blind study.
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(evaluable) achieved 5% weight loss
versus 28% of placebo-administered
subjects. Reductions in weight ap-
peared dose dependent for the pram-
lintide twice-daily but not the
pramlintide three-times-daily arms
(Fig. 1). Weight loss was accompanied
by reductions in waist circumference
with several pramlintide dose arms
achieving statistical signiﬁcance versus
placebo (online appendix Table 1).
Single-blind extension. In the exten-
sion (12-month evaluable n  146), ini-
tialweightlosswaslargelyregainedinthe
placebo group but maintained or contin-
ued in all but the pramlintide 120 g
b.i.d. arm (Fig. 1A and B). Excluding 120
g b.i.d., weight loss from baseline to
month 12 in the pramlintide arms ranged
from6.33.5to8.02.0kg(evaluable
6.0  2.8 to 7.9  1.9%; ITT-LOCF
6.1  2.4 to 6.8  1.4 kg [5.5  2.0 to
6.6  1.3%]) versus 0.8  1.3 kg (evalu-
able 1.1  1.3%; ITT-LOCF 2.4  1.1 kg
[2.2  1.0%]) with placebo. Pramlintide
120 g t.i.d., 240 g t.i.d., and 360 g
b.i.d. and t.i.d. achieved statistically sig-
niﬁcant weight loss versus placebo (12-
month evaluable and 12-month ITT-
LOCF P  0.05) (Fig. 1A and B). In these
arms, 41–65% of pramlintide-treated
subjects achieved 5% weight loss from
baseline to month 12 (placebo 18%) (Fig.
2A). In the lowest doses from each dosing
regimen achieving statistically signiﬁcant
absolute weight loss in the 4-month dou-
ble-blind study, 40 and 43% of subjects
receiving 120 g t.i.d. and 360 g b.i.d.
achieved 10% weight loss at month 12
(placebo 12%) (Fig. 2B). Similar to at
month 4, reductions in weight appeared
dose dependent for the pramlintide twice
daily but not three times daily arms. Sub-
jects treated with pramlintide 120 g
t.i.d., 240 g t.i.d., and 360 g b.i.d. also
experienced signiﬁcant reductions in
waist circumference versus placebo (P 
0.05) (online appendix Table 1).
Despite close-to-normal mean base-
line values for lipoprotein proﬁles and
blood pressure in this obese but relatively
healthy study population, fasting lipid
concentrations and blood pressure
trended toward improvements with
pramlintide treatment (online appendix
Table 1).
Safety and tolerability
In this study, pramlintide treatment at
doses up to 360 g t.i.d. was generally
well tolerated and no novel safety con-
cerns were identiﬁed. In the 4-month
double-blind study, nausea was the only
adverse event that occurred in the pooled
pramlintide treatment group with 5%
incidence and more frequently than with
placebo. The incidence of nausea ranged
from 9% (240 g t.i.d.) to 29% (360 g
t.i.d.) for the various pramlintide treat-
mentarmsversus2%forplacebo.Nausea
was generally mild to moderate and de-
creased over time. There was one case of
severenausea(360gt.i.d.)and12with-
drawals due to nausea (1 each for 120 g
b.i.d. and t.i.d. and 240 g t.i.d. arms, 2
each for 240 g b.i.d. and 360 g b.i.d.
arms, and 5 in the 360 g t.i.d. arm).
During the single-blind extension,
the incidence of nausea ranged from 0 to
9% in the pramlintide treatment arms vs-
ersus 0% for placebo (online appendix
Table 2). There were no reports of severe
nauseaorwithdrawalsduetonausea.The
most frequent adverse event in the exten-
sion was upper respiratory tract infection
(11.5% in the pooled pramlintide treat-
ment group and 14.8% with placebo).
Weight loss was dissociated from nausea,
assubjectswhodidnotexperiencenausea
during the study achieved reductions in
bodyweightsimilartothoseintheoverall
population (online appendix Fig. 1).
CONCLUSIONS—Consistent with
theirobjectives,thepresentstudyandex-
tension provide important new insights
into the safety and weight loss efﬁcacy of
pramlintide over a range of doses and
dose frequencies. Our ﬁndings show that
pramlintide in conjunction with LSI in-
duces weight loss that is durable up to 12
months.
Dose range and frequency
In previous obesity studies, pramlintide
doses were 180 to 240 g t.i.d. (8,9). In
the present study, we examined three
three-times-daily dosing regimens: 120
g (currently approved for patients with
type 2 diabetes), 240 g (maximum dose
previously studied [9]), and 360 g (not
previously tested). All three three-times-
dailydoseswereeffectiveover12months,
with240and360gt.i.d.providinglittle
additional beneﬁt over 120 g t.i.d. In
contrast to three-times-daily dosing regi-
mens, a clear dose-response relationship
was evident among twice-daily regimens,
whereby 120 g b.i.d. was suboptimal
and 360 g b.i.d. elicited weight loss of a
magnitude similar to the three-times-
daily regimens. Thus, at higher doses,
twice-dailydosingappearstobeafeasible
pramlintide regimen for weight loss.
The aforementioned dose-ranging
ﬁndings may be explained by pramlin-
tide’s pharmacokinetic proﬁle. Following
injection, plasma pramlintide peaks at
30 min and declines steadily thereafter
(t1/2  50 min) (3). With three-times-
daily dosing regimens, pramlintide was
administered before each meal and mean
weight loss was similar across three-
times-daily arms, suggesting that doses of
120 g or higher provided sufﬁcient
premiddaymealexposureacrossalldoses
studied. In contrast, pramlintide was not
administered before the midday meal in
the twice-daily arms, therefore higher
morning doses were likely required to
achieve sufﬁcient lunchtime exposure.
With respect to dose selection for fu-
ture studies, our results indicate that ad-
equate weight loss efﬁcacy and safety can
be achieved with both three-times- and
twice-daily regimens. Although 120 g
t.i.d. is commensurate with the pramlin-
tide dosing regimen currently approved
for the treatment of type 2 diabetes (12),
in the present study in obese subjects
without diabetes, 360 g b.i.d. emerged
as an equally effective dose for weight
loss. Although the incidence of nausea
was slightly greater with 360 g b.i.d.
thanwiththelower120gt.i.d.regimen,
nausea was generally mild and transient
and no other safety issues were identiﬁed
at this higher dose.
LSI
In this study, pramlintide’s effect was ev-
ident when used in conjunction with
structured LSI, which was important to
establish because nonpharmacological
treatments are a cornerstone of weight
managementandofﬁcialtreatmentguide-
lines recommend that pharmacological
agents be tested in combination with LSI
(13,14). Weight loss at 4 months
achieved with the most effective pram-
lintidedoseregimensplusLSIwasmore
than twice that obtained with LSI alone
(placebo).
Rather than choosing a speciﬁc, pre-
scriptive low-calorie diet or exercise pro-
gram, the present study used LEARN, a
well-established and ﬂexible program
aimed at making gradual changes in life-
style,includinghealthyeatingandbehav-
ior modiﬁcation. LEARN has been
extensively studied in nonpharmacologi-
cal and pharmacological intervention
studies (10,15).
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DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1819Figure1—Changesinbodyweight(kg)frombaseline(month0)fortwice-daily(A)andthree-times-daily(B)dosingregimens.Forthedouble-blindstudy,
dataarepresentedfrommonths0–4forthe4-monthevaluablepopulation(n270).Forthesingle-blindextension,dataarepresentedfrommonths4–12
forthe12-monthevaluablepopulation(n146)andat12monthsforthe12-monthITTpopulation(LOCF)(n209).Therearetwodatapointsforthe
4-monthassessment:oneassessmentforsubjectsendingthedouble-blindstudyandanotherforsubjectsenteringthesingle-blindextension.Forclarity,only
month 4 and month 12 signiﬁcance for double-blind study and single-blind extension, respectively, are depicted. Eplacebo; Œ120 g pramlintide; ‚
 240 g pramlintide; F  360 g pramlintide. Data are mean  SE. *P  0.05 and **P  0.01 for each pramlintide treatment group versus placebo.
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To obtain insights into the long-term
safety and efﬁcacy of pramlintide in obe-
sity, we instituted an extension protocol
to the 4-month dose-ranging study.
Rather than reassigning all subjects to
open-label pramlintide, we chose to
maintain a single-blind design and con-
tinue all subjects on their preexisting
treatment, including placebo administra-
tion, so as to better understand the inter-
action between the drug effect and LSI
over 12 months.
Consistent with clinical practice ex-
perience, the initial weight loss obtained
with LSI alone (placebo) was not main-
tained but was followed by gradual
weight regain. Unlike placebo, 4-month
weight loss was maintained over 12
months in all but the lowest pramlintide
twice-daily arm. This is consistent with
ﬁndingsfrom1-yearpramlintidediabetes
studies, which also showed durable
weight loss over 1 year (12,16,17).
Assessment of the durability of
pramlintide-induced weight loss in the
present study is limited by several fac-
tors. These include a relatively high at-
trition rate, a common, well-recognized
problem in obesity pharmacotherapy
studies (18), and the possibility of self-
selection bias. Of note, subjects were
not initially recruited for a long-term
study,andonly77%and50%ofthe
baselineevaluableandITTpopulations,
respectively,enteredintotheextension.
Nonetheless, the majority of subjects
who entered into the extension com-
pleted 12 months of treatment. More-
over, all pramlintide arms that achieved
signiﬁcant weight loss at month 12 in
the evaluable population also achieved
signiﬁcant (albeit more moderate)
weight loss in the ITT-LOCF analysis.
Although the aforementioned factors,
and differences in study designs, make
it difﬁcult to contextualize pramlin-
tide’s long-term efﬁcacy, it is notewor-
thy that the proportion of subjects
achieving 5 and 10% weight loss at 1
year compares quite favorably to the re-
sults reported with oral weight loss
medications (15,19,20).
Safety and tolerability
Attempts to reduce food intake and
bodyweightwithcentrallyactingsmall-
molecule anorectics have been repeat-
edly hampered by safety concerns (1).
Although the present study with pram-
lintide included a relatively small num-
berofsubjects,nonovelsafetyconcerns
were identiﬁed. This is consistent with
the concept that peptide hormone ther-
apeutics based on naturally occurring
satiety/satiation signals may hold prom-
ise as an alternative to small-molecule
anorectics and may be potential candi-
dates for combination therapy. Nausea,
the most common tolerability-related
adverse event with pramlintide treat-
ment, was mild and transient. As in pre-
Figure 2—Proportion of 12-month evaluable subjects who achieved 5% (A) and 10% (B) weight loss from baseline (month 0) to month 12.
Changes in body weight from baseline (month 0) to month 12 for each 12-month evaluable individual in the placebo (C), pramlintide 120 g t.i.d.
(D), and pramlintide 360 g b.i.d. (E) treatment arms. *P  0.05 for each pramlintide treatment group versus placebo.
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weight loss was clearly dissociable from
the occurrence of nausea.
Previous studies have suggested that
amylin analogs, such as pramlintide, may
be viable components of a combinatorial
peptide approach to obesity treatment
(21). In diet-induced obese rats, amylin
induced synergistic, fat-speciﬁc weight
loss when coadministered with leptin, a
long-term adiposity signal (22). In a re-
cently published, 24-week translational
clinical research study in overweight/
obese subjects, combination treatment
with pramlintide (360 g b.i.d.) and re-
combinant human leptin (R-met-Hu-
Leptin, meterleptin, 5 mg b.i.d.) resulted
in 12.7% mean weight loss from enroll-
ment, signiﬁcantly more than treatment
with pramlintide or meterleptin alone
(8.1 and 8.4%, respectively; P  0.001)
(22). Further development of a pramlin-
tide/meterleptin combination product for
obesity is currently underway. In conclu-
sion, although larger longer-term conﬁr-
matory studies are required to determine
its efﬁcacy and safety for weight loss,
alone or in combination, clinical ﬁndings
obtained to date support the potential of
pramlintide as part of a novel, integrated
neurohormonal approach for the man-
agement of obesity.
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